Harbour BioMed's LET003 IND Accepted in China: First Antibody Designed With the Hu-mAtrIx AI Platform Reaches Regulatory Filing for Overweight and Obesity
Harbour BioMed said China's National Medical Products Administration has accepted its IND application for LET003, a monoclonal antibody targeting ACVR2A/2B for overweight or obesity, and the company's first candidate developed with its Hu-mAtrIx AI platform. The company reports that in preclinical studies LET003 showed pharmacokinetics superior to several competitor molecules and, combined with semaglutide, enhanced fat reduction while preserving lean mass. Acceptance starts regulatory review only; LET003 has not entered clinical testing, and its safety and efficacy in people remain to be assessed.